- Home
- CROX vs GKOS Comparison
CROX vs GKOS Comparison
Compare CROX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- GKOS
- Stock Information
- Founded
- CROX 1999
- GKOS 1998
- Country
- CROX United States
- GKOS United States
- Employees
- CROX N/A
- GKOS N/A
- Industry
- CROX Shoe Manufacturing
- GKOS Medical/Dental Instruments
- Sector
- CROX Consumer Discretionary
- GKOS Health Care
- Exchange
- CROX Nasdaq
- GKOS Nasdaq
- Market Cap
- CROX 5.6B
- GKOS 5.8B
- IPO Year
- CROX 2006
- GKOS 2015
- Fundamental
- Price
- CROX $86.29
- GKOS $96.65
- Analyst Decision
- CROX Buy
- GKOS Strong Buy
- Analyst Count
- CROX 12
- GKOS 12
- Target Price
- CROX $104.18
- GKOS $131.17
- AVG Volume (30 Days)
- CROX 2.9M
- GKOS 827.0K
- Earning Date
- CROX 08-07-2025
- GKOS 07-30-2025
- Dividend Yield
- CROX N/A
- GKOS N/A
- EPS Growth
- CROX N/A
- GKOS N/A
- EPS
- CROX 4.12
- GKOS N/A
- Revenue
- CROX $4,138,679,000.00
- GKOS $432,953,000.00
- Revenue This Year
- CROX N/A
- GKOS $28.79
- Revenue Next Year
- CROX $0.71
- GKOS $25.65
- P/E Ratio
- CROX $20.96
- GKOS N/A
- Revenue Growth
- CROX 2.04
- GKOS 26.70
- 52 Week Low
- CROX $73.76
- GKOS $77.10
- 52 Week High
- CROX $151.13
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- CROX 44.60
- GKOS 59.33
- Support Level
- CROX $84.91
- GKOS $91.43
- Resistance Level
- CROX $87.12
- GKOS $94.71
- Average True Range (ATR)
- CROX 2.42
- GKOS 2.71
- MACD
- CROX 0.95
- GKOS 1.08
- Stochastic Oscillator
- CROX 97.54
- GKOS 100.00
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.